Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Egevad

Showing results (131-140 of 379) with videos related to

Pageof 38
Sort By:
Cancer Medicine|January 24, 2013
Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancerAzharuddin Sajid Syed Khaja, Lars Egevad, Leszek Helczynski, et al.
Pathology|October 30, 2020
Staging of renal cell carcinoma: current progress and potential advancesBrett Delahunt, John N Eble, Hemamali Samaratunga, et al.
Histopathology|March 19, 2016
Reply: Gleason and Fuhrman no longer make the gradeBrett Delahunt, Lars Egevad, Hemamali Samaratunga, et al.
Medical Image Analysis|July 11, 2025
Hierarchical Vision Transformers for prostate biopsy grading: Towards bridging the generalization gapClément Grisi, Kimmo Kartasalo, Martin Eklund, et al.
Scandinavian Journal of Urology and Nephrology|March 29, 2012
Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillanceAndreas Josefsson, Pernilla Wikström, Lars Egevad, et al.
Journal of Clinical Pathology|February 9, 2020
Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomyPeter Ström, Tobias Nordström, Brett Delahunt, et al.
Journal of Clinical Pathology|March 13, 2025
Time trends in Gleason score distribution among Gleason score 8 and 9-10 cancersLars Egevad, Chiara Micoli, Brett Delahunt, et al.
Scandinavian Journal of Urology and Nephrology|November 25, 2010
GAD1 is a biomarker for benign and malignant prostatic tissueSara Jonmarker Jaraj, Martin Augsten, Lars Häggarth, et al.
Scandinavian Journal of Urology and Nephrology|November 2, 2010
Diagnostic biomarkers of prostate cancerLars Häggarth, Christina Hägglöf, Sara Jonmarker Jaraj, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|May 19, 2010
Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissueAlexander Valdman, Sara Jonmarker Jaraj, Eva Compérat, et al.
Pageof 38

Showing results (131-140 of 379) with videos related to

Sort By:
Pageof 38
Cancer Medicine|January 24, 2013
Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancerAzharuddin Sajid Syed Khaja, Lars Egevad, Leszek Helczynski, et al.
Pathology|October 30, 2020
Staging of renal cell carcinoma: current progress and potential advancesBrett Delahunt, John N Eble, Hemamali Samaratunga, et al.
Histopathology|March 19, 2016
Reply: Gleason and Fuhrman no longer make the gradeBrett Delahunt, Lars Egevad, Hemamali Samaratunga, et al.
Medical Image Analysis|July 11, 2025
Hierarchical Vision Transformers for prostate biopsy grading: Towards bridging the generalization gapClément Grisi, Kimmo Kartasalo, Martin Eklund, et al.
Scandinavian Journal of Urology and Nephrology|March 29, 2012
Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillanceAndreas Josefsson, Pernilla Wikström, Lars Egevad, et al.
Journal of Clinical Pathology|February 9, 2020
Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomyPeter Ström, Tobias Nordström, Brett Delahunt, et al.
Journal of Clinical Pathology|March 13, 2025
Time trends in Gleason score distribution among Gleason score 8 and 9-10 cancersLars Egevad, Chiara Micoli, Brett Delahunt, et al.
Scandinavian Journal of Urology and Nephrology|November 25, 2010
GAD1 is a biomarker for benign and malignant prostatic tissueSara Jonmarker Jaraj, Martin Augsten, Lars Häggarth, et al.
Scandinavian Journal of Urology and Nephrology|November 2, 2010
Diagnostic biomarkers of prostate cancerLars Häggarth, Christina Hägglöf, Sara Jonmarker Jaraj, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|May 19, 2010
Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissueAlexander Valdman, Sara Jonmarker Jaraj, Eva Compérat, et al.
Pageof 38